For Referring Physicians & Clinicians

Your Referral Pathway to Belaray Is Gone — Your Voice Can Restore It

When Healthfirst terminated its contract with CHS, Belaray Dermatology's 20-year network participation ended in May 2026 through no action of the practice. Belaray immediately reapplied and expected reinstatement by August 1; instead, Healthfirst denied the application in August, citing "current network needs." If that decision affects your patients and your referrals, the people who decide — legislators, NYS DOH, and Healthfirst network management — need to hear it from clinicians. Answer a few questions and we'll draft three professional letters for your review. About 3 minutes.

Please do not include any patient-identifying information. Speak about your panel in general terms — the letters are written that way automatically. Your answers are used only to draft your letters and are not stored on this site. You review and edit everything before sending.

About you

Your name

Credentials

Specialty

Practice name (optional)

Practice county

Town (optional)

How long have you referred patients to Belaray?

How are your patients affected?

Check everything that reflects your actual experience since May 2026. New York's managed-care standards generally expect a specialist appointment within 4–6 weeks — front-line observations that this isn't happening are exactly what regulators act on.

My Healthfirst patients have lost timely dermatology access through my established referral pathway Patients report waits well beyond the 4–6 week standard at other in-network dermatologists Lost referral pathway for Mohs surgery with same-day oculoplastic reconstruction Patients lost access to phototherapy Lost urgent-access pathway that kept patients out of the emergency department Patients lost language-concordant care (Spanish, Hindi, Punjabi, Bengali) Continuity interrupted for melanoma surveillance / complex patients

How is your practice affected?

I rely on Belaray for prompt evaluation of concerning lesions We co-manage complex patients (biologics, autoimmune, oncology-related skin disease) They reliably communicate consult findings back to me I have no comparable in-network referral option for Healthfirst patients My staff spends significant time hunting for alternatives I'm concerned about delayed skin-cancer diagnoses from this access gap

In your own words (optional)

What should the people making this decision understand, from where you sit? No patient identifiers.

I understand the letters will be generated from my answers; I will review and edit them before deciding whether to send. They contain no patient-identifying information and are sent by me, in my own professional capacity.

Your Referral Pathway to Belaray Is Gone — Your Voice Can Restore It

About you

How are your patients affected?

How is your practice affected?

In your own words (optional)

📬 Letter 1: To your NY State legislators

🏛️ Letter 2: To the NYS Department of Health

📞 Letter 3: To Healthfirst Provider Services